Skip to main content
Top
Published in: Hepatology International 2/2024

Open Access 17-04-2023 | Liver Transplantation | Original Article

OHCCPredictor: an online risk stratification model for predicting survival duration of older patients with hepatocellular carcinoma

Authors: Juntao Tan, Yue Yu, Xiantian Lin, Yuxin He, Wen Jin, Hong Qian, Ying Li, Xiaomei Xu, Yuxi Zhao, Jianwen Ning, Zhengyu Zhang, Jingjing Chen, Xiaoxin Wu

Published in: Hepatology International | Issue 2/2024

Login to get access

Abstract

Background

Although the elderly constitute more than a third of hepatocellular carcinoma (HCC) patients, they have not been adequately represented in treatment and prognosis studies. Thus, there is not enough evidence to guide the treatment of such patients. The objective of this study is to identify the prognostic factors of older patients with HCC and to construct a new prognostic model for predicting their overall survival (OS).

Methods

2,721 HCC patients aged ≥ 65 were extracted from the public database-Surveillance, Epidemiology, and End Results (SEER) and randomly divided into a training set and an internal validation set with a ratio of 7:3. 101 patients diagnosed from 2008 to 2017 in the First Affiliated Hospital of Zhejiang University School of Medicine were identified as the external validation set. Univariate cox regression analyses and multivariate cox regression analyses were adopted to identify these independent prognostic factors. A predictive nomogram-based risk stratification model was proposed and evaluated using area under the receiver operating characteristic curve (AUC), calibration curves, and a decision curve analysis (DCA).

Results

These attributes including age, sex, marital status, T stage, N stage, surgery, chemotherapy, tumor size, alpha-fetoprotein level, fibrosis score, bone metastasis, lung metastasis, and grade were the independent prognostic factors for older patients with HCC while predicting survival duration. We found that the nomogram provided a good assessment of OS at 1, 3, and 5 years in older patients with HCC (1-year OS: (training set: AUC = 0.823 (95%CI 0.803–0.845); internal validation set: AUC = 0.847 (95%CI 0.818–0.876); external validation set: AUC = 0.732 (95%CI 0.521–0.943)); 3-year OS: (training set: AUC = 0.813 (95%CI 0.790–0.837); internal validation set: AUC = 0.844 (95%CI 0.812–0.876); external validation set: AUC = 0.780 (95%CI 0.674–0.887)); 5-year OS: (training set: AUC = 0.839 (95%CI 0.806–0.872); internal validation set: AUC = 0.800 (95%CI 0.751–0.849); external validation set: AUC = 0.821 (95%CI 0.727–0.914)). The calibration curves showed that the nomogram was with strong calibration. The DCA indicated that the nomogram can be used as an effective tool in clinical practice. The risk stratification of all subgroups was statistically significant (p < 0.05). In the stratification analysis of surgery, larger resection (LR) achieved a better survival curve than local destruction (LD), but a worse one than segmental resection (SR) and liver transplantation (LT) (p < 0.0001). With the consideration of the friendship to clinicians, we further developed an online interface (OHCCPredictor) for such a predictive function (https://​juntaotan.​shinyapps.​io/​dynnomapp_​hcc/​). With such an easily obtained online tool, clinicians will be provided helpful assistance in formulating personalized therapy to assess the prognosis of older patients with HCC.

Conclusions

Age, sex, marital status, T stage, N stage, surgery, chemotherapy, tumor size, AFP level, fibrosis score, bone metastasis, lung metastasis, and grade were independent prognostic factors for elderly patients with HCC. The constructed nomogram model based on the above factors could accurately predict the prognosis of such patients. Besides, the developed online web interface of the predictive model provide easily obtained access for clinicians.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9(6):765–779PubMedCrossRef Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9(6):765–779PubMedCrossRef
2.
go back to reference Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347–354PubMedCrossRef Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347–354PubMedCrossRef
3.
go back to reference Hyuna S, Jacques F, Siegel RL, Mathieu L, Isabelle S, Ahmedin J, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2021;71(3):209–249CrossRef Hyuna S, Jacques F, Siegel RL, Mathieu L, Isabelle S, Ahmedin J, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2021;71(3):209–249CrossRef
4.
go back to reference El-Serag HB, Rudolph KL. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology. 2007;132(7):2557–2576PubMedCrossRef El-Serag HB, Rudolph KL. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis. Gastroenterology. 2007;132(7):2557–2576PubMedCrossRef
5.
go back to reference Li C, Xu X. Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma. Cell Mol Life Sci. 2019;76(21):4203–4219PubMedCrossRef Li C, Xu X. Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma. Cell Mol Life Sci. 2019;76(21):4203–4219PubMedCrossRef
6.
go back to reference Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–1718PubMedCrossRef Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706–1718PubMedCrossRef
7.
go back to reference Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380PubMedCrossRef Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380PubMedCrossRef
8.
go back to reference Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hep Int. 2017;11(4):317–370CrossRef Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hep Int. 2017;11(4):317–370CrossRef
9.
go back to reference Somasundaram S, Kelley RK, Venook AP. A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol. 2013;2(4):33 Somasundaram S, Kelley RK, Venook AP. A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol. 2013;2(4):33
10.
go back to reference Hung AK, Guy J. Hepatocellular carcinoma in the elderly:Meta-analysis and systematic literature review. World J Gastroenterol. 2015;21(42):12197–12210PubMedPubMedCentralCrossRef Hung AK, Guy J. Hepatocellular carcinoma in the elderly:Meta-analysis and systematic literature review. World J Gastroenterol. 2015;21(42):12197–12210PubMedPubMedCentralCrossRef
11.
go back to reference Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758–2765PubMedCrossRef Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758–2765PubMedCrossRef
12.
go back to reference Dingde Y, Jiamu Q, Jian W, Guoqiang L, Beicheng S, Qingxiang X. A new clinical nomogram from the TCGA database to predict the prognosis of hepatocellular carcinoma &#13. Front Oncol. 2021;11:698980CrossRef Dingde Y, Jiamu Q, Jian W, Guoqiang L, Beicheng S, Qingxiang X. A new clinical nomogram from the TCGA database to predict the prognosis of hepatocellular carcinoma &#13. Front Oncol. 2021;11:698980CrossRef
13.
go back to reference Xueping W, Minjie M, Zhonglian H, Lin Z, Huilan L, Jianhua L, et al. Development and validation of a prognostic nomogram in AFP-negative hepatocellular carcinoma. Int J Biol Sci. 2019;15(1):221–228CrossRef Xueping W, Minjie M, Zhonglian H, Lin Z, Huilan L, Jianhua L, et al. Development and validation of a prognostic nomogram in AFP-negative hepatocellular carcinoma. Int J Biol Sci. 2019;15(1):221–228CrossRef
14.
go back to reference Kena Z, Qiang Z, Congbo C. A genomic-clinicopathologic nomogram for predicting overall survival of hepatocellular carcinoma. BMC Cancer. 2020;20(1):1176CrossRef Kena Z, Qiang Z, Congbo C. A genomic-clinicopathologic nomogram for predicting overall survival of hepatocellular carcinoma. BMC Cancer. 2020;20(1):1176CrossRef
15.
go back to reference Park HS, Lloyd S, Decker RH, Wilson LD, Yu JB. Overview of the surveillance, epidemiology, and end results database: evolution, data variables, and quality assurance. Curr Probl Cancer. 2012;36(4):183–190PubMedCrossRef Park HS, Lloyd S, Decker RH, Wilson LD, Yu JB. Overview of the surveillance, epidemiology, and end results database: evolution, data variables, and quality assurance. Curr Probl Cancer. 2012;36(4):183–190PubMedCrossRef
16.
go back to reference Zhuang W, Chen J, Li Y, Liu W. Valuation of lymph node dissection in localized high-risk renal cell cancer using X-tile software. Int Urol Nephrol. 2020;52(2):253–262PubMedCrossRef Zhuang W, Chen J, Li Y, Liu W. Valuation of lymph node dissection in localized high-risk renal cell cancer using X-tile software. Int Urol Nephrol. 2020;52(2):253–262PubMedCrossRef
17.
go back to reference Vickers AJ, Van Calster B, Steyerberg E. Decision curves, calibration, and subgroups. J Clinical Oncol. 2017;35(4):472–473CrossRef Vickers AJ, Van Calster B, Steyerberg E. Decision curves, calibration, and subgroups. J Clinical Oncol. 2017;35(4):472–473CrossRef
18.
go back to reference Liu K, Huang G, Chang P, Zhang W, Li T, Dai Z, et al. Construction and validation of a nomogram for predicting cancer-specific survival in hepatocellular carcinoma patients. Sci Rep. 2020;10(1):21376PubMedPubMedCentralCrossRef Liu K, Huang G, Chang P, Zhang W, Li T, Dai Z, et al. Construction and validation of a nomogram for predicting cancer-specific survival in hepatocellular carcinoma patients. Sci Rep. 2020;10(1):21376PubMedPubMedCentralCrossRef
20.
go back to reference Wan S, Nie Y, Zhu X. Development of a prognostic scoring model for predicting the survival of elderly patients with hepatocellular carcinoma. PeerJ. 2020;8: e8497PubMedPubMedCentralCrossRef Wan S, Nie Y, Zhu X. Development of a prognostic scoring model for predicting the survival of elderly patients with hepatocellular carcinoma. PeerJ. 2020;8: e8497PubMedPubMedCentralCrossRef
21.
go back to reference He T, Chen T, Liu X, Zhang B, Yue S, Cao J, et al. A web-based prediction model for cancer-specific survival of elderly patients with early hepatocellular carcinoma: a study based on SEER database. Front Public Health. 2022;9: 789026PubMedPubMedCentralCrossRef He T, Chen T, Liu X, Zhang B, Yue S, Cao J, et al. A web-based prediction model for cancer-specific survival of elderly patients with early hepatocellular carcinoma: a study based on SEER database. Front Public Health. 2022;9: 789026PubMedPubMedCentralCrossRef
22.
go back to reference Liu Z, Pu Y, Bao Y, He S. Investigation of potential molecular biomarkers for diagnosis and prognosis of AFP-negative HCC. Int J General Med. 2021;14:4369–4380CrossRef Liu Z, Pu Y, Bao Y, He S. Investigation of potential molecular biomarkers for diagnosis and prognosis of AFP-negative HCC. Int J General Med. 2021;14:4369–4380CrossRef
23.
go back to reference Luo P, Wu S, Yu Y, Ming X, Li S, Zuo X, et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol Oncol Res. 2020;26(2):599–603PubMedCrossRef Luo P, Wu S, Yu Y, Ming X, Li S, Zuo X, et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Pathol Oncol Res. 2020;26(2):599–603PubMedCrossRef
24.
go back to reference Tseng TC, Choi J, Nguyen MH, Peng CY, Siakavellas S, Papatheodoridis G, et al. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. Hep Int. 2021;15(1):105–113CrossRef Tseng TC, Choi J, Nguyen MH, Peng CY, Siakavellas S, Papatheodoridis G, et al. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. Hep Int. 2021;15(1):105–113CrossRef
25.
go back to reference Wu C, Ren X, Zhang Q. Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung metastasis: a population-based study. Cancer Manag Res. 2019;11:2759–2768PubMedPubMedCentralCrossRef Wu C, Ren X, Zhang Q. Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung metastasis: a population-based study. Cancer Manag Res. 2019;11:2759–2768PubMedPubMedCentralCrossRef
26.
go back to reference Chuan H, Jiaxin Y, Zhangheng H, Chuan L, Yijun L, Yuexin T, et al. Diagnostic and prognostic nomograms for bone metastasis in hepatocellular carcinoma. BMC Cancer. 2020;20(1):494CrossRef Chuan H, Jiaxin Y, Zhangheng H, Chuan L, Yijun L, Yuexin T, et al. Diagnostic and prognostic nomograms for bone metastasis in hepatocellular carcinoma. BMC Cancer. 2020;20(1):494CrossRef
27.
go back to reference Burdett N, Vincent AD, O’Callaghan M, Kichenadasse G. Competing risks in older patients with cancer: a systematic review of geriatric oncology trials. J Natl Cancer Inst. 2018;110(8):825–830PubMedCrossRef Burdett N, Vincent AD, O’Callaghan M, Kichenadasse G. Competing risks in older patients with cancer: a systematic review of geriatric oncology trials. J Natl Cancer Inst. 2018;110(8):825–830PubMedCrossRef
28.
go back to reference Lee L, Cheung WY, Atkinson E, Krzyzanowska MK. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol. 2011;29(1):106–117PubMedCrossRef Lee L, Cheung WY, Atkinson E, Krzyzanowska MK. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol. 2011;29(1):106–117PubMedCrossRef
30.
go back to reference Attili VS, Babu KG, Lokanatha D, Bapsy PP, Ramachandra C, Rajshekar H. Bone metastasis in hepatocellular carcinoma: need for reappraisal of treatment. J Cancer Res Ther. 2008;4(2):93–94PubMedCrossRef Attili VS, Babu KG, Lokanatha D, Bapsy PP, Ramachandra C, Rajshekar H. Bone metastasis in hepatocellular carcinoma: need for reappraisal of treatment. J Cancer Res Ther. 2008;4(2):93–94PubMedCrossRef
31.
go back to reference Tang Y, Li K, Cai Z, Xie Y, Tan X, Su C, et al. HSP90α combined with AFP and TK1 improved the diagnostic value for hepatocellular carcinoma. Biomark Med. 2020;14(10):869–878PubMedCrossRef Tang Y, Li K, Cai Z, Xie Y, Tan X, Su C, et al. HSP90α combined with AFP and TK1 improved the diagnostic value for hepatocellular carcinoma. Biomark Med. 2020;14(10):869–878PubMedCrossRef
32.
go back to reference Wang Y, Zhang C, Zhang P, Guo G, Jiang T, Zhao X, et al. Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma. Cancer Med. 2018;7(5):1670–1679PubMedPubMedCentralCrossRef Wang Y, Zhang C, Zhang P, Guo G, Jiang T, Zhao X, et al. Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma. Cancer Med. 2018;7(5):1670–1679PubMedPubMedCentralCrossRef
33.
go back to reference Yang A, Xiao W, Chen D, Wei X, Huang S, Lin Y, et al. The power of tumor sizes in predicting the survival of solitary hepatocellular carcinoma patients. Cancer Med. 2018;7(12):6040–6050PubMedPubMedCentralCrossRef Yang A, Xiao W, Chen D, Wei X, Huang S, Lin Y, et al. The power of tumor sizes in predicting the survival of solitary hepatocellular carcinoma patients. Cancer Med. 2018;7(12):6040–6050PubMedPubMedCentralCrossRef
34.
go back to reference Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870PubMedPubMedCentralCrossRef Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870PubMedPubMedCentralCrossRef
35.
go back to reference Qiu WQ, Shi JF, Guo LW, Mao AY, Huang HY, Hu GY, et al. Medical expenditure for liver cancer in urban China: a 10-year multicenter retrospective survey (2002–2011). J Cancer Res Ther. 2018;14(1):163–170PubMedCrossRef Qiu WQ, Shi JF, Guo LW, Mao AY, Huang HY, Hu GY, et al. Medical expenditure for liver cancer in urban China: a 10-year multicenter retrospective survey (2002–2011). J Cancer Res Ther. 2018;14(1):163–170PubMedCrossRef
36.
go back to reference Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med. 2021;15(2):155–169PubMedCrossRef Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med. 2021;15(2):155–169PubMedCrossRef
37.
go back to reference Adhoute X, Pénaranda G, Raoul JL, Bollon E, Pol B, Letreut YP, et al. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization. Eur J Gastroenterol Hepatol. 2017;29(6):706–715PubMedCrossRef Adhoute X, Pénaranda G, Raoul JL, Bollon E, Pol B, Letreut YP, et al. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization. Eur J Gastroenterol Hepatol. 2017;29(6):706–715PubMedCrossRef
38.
go back to reference Xiaohong S, Huikai L, Feng W, Ti Z, Yunlong C, Qiang L. Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma. World J Surg. 2010;34(5):1028–1033PubMedCrossRef Xiaohong S, Huikai L, Feng W, Ti Z, Yunlong C, Qiang L. Clinical significance of lymph node metastasis in patients undergoing partial hepatectomy for hepatocellular carcinoma. World J Surg. 2010;34(5):1028–1033PubMedCrossRef
39.
go back to reference Xing L, Guo HB, Kan JL, Liu SG, Lv HT, Liu JH, et al. Clinical outcome of open surgery versus laparoscopic surgery for cirrhotic hepatocellular carcinoma patients: a meta-analysis. Eur J Gastroenterol Hepatol. 2019;32(2):239–245CrossRef Xing L, Guo HB, Kan JL, Liu SG, Lv HT, Liu JH, et al. Clinical outcome of open surgery versus laparoscopic surgery for cirrhotic hepatocellular carcinoma patients: a meta-analysis. Eur J Gastroenterol Hepatol. 2019;32(2):239–245CrossRef
40.
go back to reference Zheng Z, Liang W, Wang D, Schroder PM, Ju W, Wu L, et al. Adjuvant chemotherapy for patients with primary hepatocellular carcinoma: a meta-analysis. Int J Cancer. 2015;136(6):E751–E759PubMedCrossRef Zheng Z, Liang W, Wang D, Schroder PM, Ju W, Wu L, et al. Adjuvant chemotherapy for patients with primary hepatocellular carcinoma: a meta-analysis. Int J Cancer. 2015;136(6):E751–E759PubMedCrossRef
41.
go back to reference Lei C, Tao S, Shi C, Yanqiao R, Fan Y, Chuansheng Z. The efficacy of surgery in advanced hepatocellular carcinoma: a cohort study. World J Surg Oncol. 2020;18(1):119CrossRef Lei C, Tao S, Shi C, Yanqiao R, Fan Y, Chuansheng Z. The efficacy of surgery in advanced hepatocellular carcinoma: a cohort study. World J Surg Oncol. 2020;18(1):119CrossRef
42.
go back to reference Pugh RN. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(23):2497–2498CrossRef Pugh RN. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(23):2497–2498CrossRef
43.
go back to reference Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34PubMedCrossRef Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34PubMedCrossRef
44.
go back to reference Bin LR, Yang Z, Ke HM, Sheng WD, Yun BX, Xing HY, et al. Hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin with or without sorafenib as initial treatment for advanced hepatocellular carcinoma. Front Oncol. 2021;11: 619461CrossRef Bin LR, Yang Z, Ke HM, Sheng WD, Yun BX, Xing HY, et al. Hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin with or without sorafenib as initial treatment for advanced hepatocellular carcinoma. Front Oncol. 2021;11: 619461CrossRef
45.
go back to reference Shaya FT, Breunig IM, Seal B, Mullins CD, Chirikov VV, Hanna N. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-medicare. Pharmacoeconomics. 2014;32(1):63–74PubMedCrossRef Shaya FT, Breunig IM, Seal B, Mullins CD, Chirikov VV, Hanna N. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-medicare. Pharmacoeconomics. 2014;32(1):63–74PubMedCrossRef
46.
go back to reference Kamarajah SK. Fibrosis score impacts survival following resection for hepatocellular carcinoma (HCC): a surveillance, end results and epidemiology (SEER) database analysis. Asian J Surg. 2018;41(6):551–561PubMedCrossRef Kamarajah SK. Fibrosis score impacts survival following resection for hepatocellular carcinoma (HCC): a surveillance, end results and epidemiology (SEER) database analysis. Asian J Surg. 2018;41(6):551–561PubMedCrossRef
47.
go back to reference Zhang QQ, Wu PY, Bahde M, Zhang LF, Zhou ZH, Liu H, et al. Do elderly patients with stage I-II hepatocellular carcinoma benefit from more radical surgeries? A population-based analysis. Front Oncol. 2020;10:479PubMedPubMedCentralCrossRef Zhang QQ, Wu PY, Bahde M, Zhang LF, Zhou ZH, Liu H, et al. Do elderly patients with stage I-II hepatocellular carcinoma benefit from more radical surgeries? A population-based analysis. Front Oncol. 2020;10:479PubMedPubMedCentralCrossRef
Metadata
Title
OHCCPredictor: an online risk stratification model for predicting survival duration of older patients with hepatocellular carcinoma
Authors
Juntao Tan
Yue Yu
Xiantian Lin
Yuxin He
Wen Jin
Hong Qian
Ying Li
Xiaomei Xu
Yuxi Zhao
Jianwen Ning
Zhengyu Zhang
Jingjing Chen
Xiaoxin Wu
Publication date
17-04-2023
Publisher
Springer India
Published in
Hepatology International / Issue 2/2024
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-023-10516-x

Other articles of this Issue 2/2024

Hepatology International 2/2024 Go to the issue

Abstracts

Abstracts

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.